Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: A subanalysis of the EPHESUS trial

European Journal of Heart Failure

Volumn 16, Issue 6, 2014, Pages 685-691

  Iqbal, Javaid ^a   Fay, Renaud ^b   Adlam, David ^c   Squire, Iain ^c   Parviz, Yasir ^a   Gunn, Julian ^a   Pitt, Bertram ^d   Zannad, Faiez ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITÉ DE LORRAINE   (France)

^c GLENFIELD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angioplasty; Eplerenone; Heart failure; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; POTASSIUM; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ANGINA PECTORIS; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION; SUDDEN CARDIAC DEATH; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84902012971     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.88     Document Type: Article

References (29)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M,. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW,. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-989.
4. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX,. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78-e140.
5. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D,. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
6. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, Kanematsu Y, Tsuchiya K, Tamaki T, Nishiyama A, Yoshizumi M,. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005; 46: 1046-1052.
7. Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, Jazbutyte V, Hahner S, Ertl G, Bauersachs J,. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2011; 32: 1275-1286.
8. Wu VC, Lo SC, Chen YL, Huang PH, Tsai CT, Liang CJ, Kuo CC, Kuo YS, Lee BC, Wu EL, Lin YH, Sun YY, Lin SL, Chen JW, Lin SJ, Wu KD,. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab 2011; 96: 3175-3183.
9. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A,. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001; 104: 467-472. (Pubitemid 32678279)
10. Wakabayashi K, Suzuki H, Sato T, Iso Y, Katagiri T, Takeyama Y,. Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int J Cardiol 2006; 107: 260-266. (Pubitemid 43075243)
11. Iqbal J, Macdonald LJ, Low L, Seckl JR, Yau CW, Walker BR, Hadoke PW,. Contribution of endogenous glucocorticoids and their intravascular metabolism by 11beta-HSDs to postangioplasty neointimal proliferation in mice. Endocrinology 2012; 153: 5896-5905.
12. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW,. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P,. Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J,. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
15. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B,. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
16. Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F,. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail 2014; 16: 143-150.
17. Keeley EC, Boura JA, Grines CL,. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20. (Pubitemid 36050955)
18. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ,. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360: 743-751. (Pubitemid 35247703)
19. Montalescot G, Pitt B, Lopez-de-Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F,. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure. ACC, San Francisco, 10 March, 2013.
20. Beygui F, Vicaut E, Ecollan P, Machecourt J, Van Belle E, Zannad F, Montalescot G,. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J 2010; 160: 642-648.
21. Hadoke PW, Iqbal J, Walker BR,. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol 2009; 156: 689-712.
22. Kayes-Wandover KM, White PC,. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000; 85: 2519-2525. (Pubitemid 32269210)
23. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M,. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917-921. (Pubitemid 43732172)
24. Amano T, Matsubara T, Izawa H, Torigoe M, Yoshida T, Hamaguchi Y, Ishii H, Miura M, Hayashi Y, Ogawa Y, Murohara T,. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol 2006; 97: 785-788.
25. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M,. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003; 41: 955-963. (Pubitemid 36706146)
26. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL,. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252-1257. (Pubitemid 38691747)
27. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, Dupuis B, Lablanche JM, Bertrand ME,. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 1995; 29: 27-32.
28. Bacchetta MD, Salemi A, Milla F, Hong MK, Tio F, Zhou Y, Chen R, Southard E, Lee LY, Mack CA, Krieger KH, Isom OW, Ko W, Borer JS, Catanzaro DF,. Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites. Am J Ther 2009; 16: 204-214.
29. Kursaklioglu H, Iyisoy A, Amasyali B, Celik T, Ozturk C, Kose S, Isik E,. Spironolactone does not prevent restenosis after coronary stenting in humans. Ann Acad Med Singapore 2004; 33: 769-774. (Pubitemid 40187881)